+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07784387

Characterizing High-Risk Non-Muscle-Invasive Bladder Cancer Diagnosis and Care A Retrospective Study in Portugal

Led by Janssen-Cilag Farmaceutica Ltda. · Updated on 2026-08-28

250

Participants Needed

1

Research Sites

1 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying people with high-risk non-muscle invasive bladder cancer HR-NMIBC in Portugal to understand how they are diagnosed, treated, and cared for in normal clinical settings. HR-NMIBC is an early form of bladder cancer limited to the bladders inner lining but has a high chance of recurring or worsening. This study collects information retrospectively from participants diagnosed between 2016 and 2020. Participants diagnosed with HR-NMIBC will have their demographic and clinical data gathered from medical records, including electronic and paper files, covering the time from diagnosis up to at least five years afterward. This study does not involve giving any drugs or treatments but focuses on observing routine clinical practice and treatment patterns over time. During the study, researchers will review records for treatment types, surgeries performed, and therapy details by tumor stage and histology. They will also assess outcomes such as recurrence-free survival, progression-free survival, overall survival, and healthcare resource use over a five-year period. No active intervention is given, and the study duration depends on data collected from past routine care.

CONDITIONS

Brief Title

A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here